The combination of the mTOR inhibitor temsirolimus (CCI-779) with chemotherapy (docetaxel) resulted in a strong antitumor activity in breast (MDA-MB-468) and prostate (PC3) xenografts and cancer cells [204]. The gene discussed is MTOR; the disease is cancer.